Evofem Biosciences, Inc. (EVFM)
USD 0.01
(-6.25%)
USD 0.01
(-6.25%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -17.37 Million USD | 82.83% |
| 2022 | -83.1 Million USD | 29.7% |
| 2021 | -165.77 Million USD | -99.15% |
| 2020 | -103.32 Million USD | -48.61% |
| 2019 | -79.12 Million USD | -52.02% |
| 2018 | -29.59 Million USD | -197.48% |
| 2017 | -105.05 Million USD | 16.98% |
| 2016 | -11.91 Million USD | 71.49% |
| 2015 | -41.96 Million USD | -338.49% |
| 2014 | -10.42 Million USD | 33.43% |
| 2013 | -14.39 Million USD | -156.37% |
| 2012 | -6.76 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -2.78 Million USD | 14.52% |
| 2024 Q2 | -1.34 Million USD | 50.95% |
| 2023 Q2 | -7.06 Million USD | -45.27% |
| 2023 Q1 | -4.86 Million USD | 70.1% |
| 2023 FY | - USD | 82.83% |
| 2023 Q4 | -3.31 Million USD | 95.5% |
| 2023 Q3 | -73.67 Million USD | -943.14% |
| 2022 Q1 | -26.17 Million USD | -6.86% |
| 2022 FY | - USD | 29.7% |
| 2022 Q4 | -16.26 Million USD | 87.21% |
| 2022 Q3 | -127.1 Million USD | -265.15% |
| 2022 Q2 | 76.96 Million USD | 393.99% |
| 2021 Q2 | -49.77 Million USD | -11.77% |
| 2021 Q3 | -13.59 Million USD | 72.69% |
| 2021 FY | - USD | -99.15% |
| 2021 Q4 | -24.49 Million USD | -80.19% |
| 2021 Q1 | -44.53 Million USD | -38.48% |
| 2020 Q1 | -19.17 Million USD | -48.97% |
| 2020 Q2 | 7.65 Million USD | 139.93% |
| 2020 Q4 | -32.16 Million USD | -39.87% |
| 2020 Q3 | -22.99 Million USD | -400.33% |
| 2020 FY | - USD | -48.61% |
| 2019 Q1 | -9.12 Million USD | 39.08% |
| 2019 Q4 | -12.87 Million USD | 9.97% |
| 2019 Q3 | -14.29 Million USD | -65.74% |
| 2019 Q2 | -8.62 Million USD | 5.48% |
| 2019 FY | - USD | -52.02% |
| 2018 FY | - USD | -197.48% |
| 2018 Q4 | -14.98 Million USD | 18.44% |
| 2018 Q3 | -18.36 Million USD | 20.75% |
| 2018 Q2 | -23.17 Million USD | -185.43% |
| 2018 Q1 | 27.12 Million USD | 1259.58% |
| 2017 Q1 | -3 Million USD | -52.22% |
| 2017 FY | - USD | 16.98% |
| 2017 Q4 | -2.33 Million USD | -30.03% |
| 2017 Q3 | -1.79 Million USD | 35.89% |
| 2017 Q2 | -2.8 Million USD | 6.5% |
| 2016 Q2 | -2.48 Million USD | 56.72% |
| 2016 Q4 | -1.97 Million USD | -7.31% |
| 2016 FY | - USD | 71.49% |
| 2016 Q3 | -1.83 Million USD | 26.07% |
| 2016 Q1 | -5.74 Million USD | 37.74% |
| 2015 Q1 | -6.62 Million USD | -103.69% |
| 2015 FY | - USD | -338.49% |
| 2015 Q4 | -9.22 Million USD | 45.59% |
| 2015 Q3 | -16.95 Million USD | -84.46% |
| 2015 Q2 | -9.19 Million USD | -38.72% |
| 2014 Q2 | -1.97 Million USD | 20.21% |
| 2014 Q1 | -2.47 Million USD | 2.11% |
| 2014 FY | - USD | 33.43% |
| 2014 Q4 | -3.25 Million USD | -74.89% |
| 2014 Q3 | -1.86 Million USD | 5.96% |
| 2013 FY | - USD | -156.37% |
| 2013 Q4 | -2.53 Million USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 75.548% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -192.971% |
| SQZ Biotechnologies Company | -64.14 Million USD | 72.919% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 118.471% |
| Mesoblast Limited | -62.38 Million USD | 72.159% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -1030.823% |
| Genus plc | 73.7 Million USD | 123.569% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -162.723% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -389.71% |
| Marizyme, Inc. | -34.28 Million USD | 49.331% |
| ContraFect Corporation | -64.99 Million USD | 73.277% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -98.016% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -283.766% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -1139.114% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -556.848% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -647.476% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -3252.984% |
| Accustem Sciences Inc. | -3.74 Million USD | -363.643% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 63.983% |
| EV Biologics, Inc. | -1.26 Million USD | -1270.812% |
| Q BioMed Inc. | -617.62 Thousand USD | -2712.372% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 586.282% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -2646.653% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -660.345% |
| Biomind Labs Inc. | -1.03 Million USD | -1578.992% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 275.863% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -142.555% |
| Skye Bioscience, Inc. | -13.54 Million USD | -28.215% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -1067.8% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -69380.0% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -347.183% |
| IMV Inc. | -35.52 Million USD | 51.103% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -9.454% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -594.255% |
| GB Sciences, Inc. | -1.41 Million USD | -1123.339% |
| Alpha Cognition Inc. | -9.7 Million USD | -78.969% |
| HST Global, Inc. | -5303.00 USD | -327450.443% |
| CSL Limited | 4.78 Billion USD | 100.363% |
| Halberd Corporation | -74.27 Thousand USD | -23284.806% |
| Enzolytics Inc. | -2.12 Million USD | -718.556% |
| Resverlogix Corp. | -11.74 Million USD | -47.931% |
| Affymax, Inc. | -14.29 Million USD | -21.511% |
| SYBLEU INC | -141.57 Thousand USD | -12169.462% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -467.088% |
| argenx SE | -216.02 Million USD | 91.959% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 68.612% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 1527.28% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -1058.845% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 4685.001% |
| AVAX Technologies, Inc. | -6.11 Million USD | -184.165% |
| Zenith Capital Corp. | -8.6 Million USD | -101.836% |
| Genscript Biotech Corporation | -248.71 Million USD | 93.016% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -99607.25% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -610.005% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -9767.952% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 56.177% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -500.555% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -1560.117% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 258428.376% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -892.572% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -804.258% |
| BioStem Technologies, Inc. | -7.55 Million USD | -129.955% |
| ONE Bio Corp. | 13.61 Million USD | 227.598% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -9492.022% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -744.434% |
| Agentix Corp. | -1.37 Million USD | -1166.26% |
| LadRx Corporation | 412.28 Thousand USD | 4313.125% |
| Cell Source, Inc. | -4.27 Million USD | -306.551% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -4630.122% |
| Regen BioPharma, Inc. | 1.46 Million USD | 1284.892% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -1753.89% |
| NovAccess Global Inc. | -1.03 Million USD | -1578.59% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 296.187% |
| Itoco Inc. | -1.86 Million USD | -829.376% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -4475.628% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -1456.452% |
| Kadimastem Ltd | -2.62 Million USD | -561.87% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -7163.224% |
| CytoDyn Inc. | -18.02 Million USD | 3.655% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -21879.273% |
| Mobile Lads Corp. | -2.24 Million USD | -675.045% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -141939.415% |
| Qrons Inc. | -40.08 Thousand USD | -43237.242% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -3476.444% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 3393.309% |
| Rebus Holdings, Inc. | -951 Thousand USD | -1726.498% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -1535.578% |
| International Stem Cell Corporation | 202 Thousand USD | 8699.01% |
| Bioxytran, Inc. | -3.82 Million USD | -354.695% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -32897.72% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -605.543% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 51.574% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -38500.0% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -534.405% |
| Neutra Corp. | -181.24 Thousand USD | -9483.607% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 13.835% |
| PureTech Health plc | -11.62 Million USD | -49.394% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 13.829% |
| IXICO plc | -707 Thousand USD | -2356.86% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -126.025% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 64.071% |
| CSL Limited | 4.73 Billion USD | 100.367% |
| Cellectis S.A. | -92.63 Million USD | 81.249% |